University of Arkansas for Medical Sciences (UAMS)
Little Rock, AR
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
MagnetisMM-20
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 1
- Has results
Accepting patients
MonumenTAL-1
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Bispecific Antibody
- GPRC5D
- Phase 2
Accepting patients
LimiTec
Phase 2, Single-Arm, Non-Inferiority Study Of Limited-Duration Teclistamab For Relapsed Refractory Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 2
- Has results
Accepting patients
High Dose Ascorbic Acid w/ Melphalan
High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
- Chemotherapy
- Post-Autologous Stem Cell Transplant
- Phase 1
Accepting patients
Triplet Induction + 1 or 2-Drug Maintenance
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
- Monoclonal Antibody
- CD38
- Randomization
- Maintenance
- Phase 3
Not yet accepting
MMulti-Immune HR
A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)
- Bispecific Antibody
- BCMA
- GPRC5D
- Phase 2